ArticlePharmacopsychiatry2023
DNA Methylation of POMC and NR3C1-1F and Its Implication in Major Depressive Disorder and Electroconvulsive Therapy.
Article in Pharmacopsychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 15 citations in OpenAlex.
- Changes in leukocytes and CRP in different treatments of major depression.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Longitudinal associations of DNA-methylation of OXT, SLC6A4 and NR3C1 genes with the treatment response in patients with depression.Scientific reports · 2026Article
- Overweight and POMC methylation: epigenetic associations with adolescent depression.BMC psychiatry · 2025Article
- Evaluation of Proopiomelanocortin (POMC) and neuropeptide Y (NPY) levels in bipolar and unipolar patients.BMC psychiatry · 2025Article
- ECT-induced primary open-angle glaucoma in a patient with unstable thyroid function: a case report.Frontiers in psychiatry · 2025Article
- Immune-inflammatory, neuroplastic, and epigenetic effects of electroconvulsive therapy in mood disorders: an overview of recent studies.Frontiers in psychiatry · 2025Review
- Unraveling epigenomic signatures and effectiveness of electroconvulsive therapy in treatment-resistant depression patients: a prospective longitudinal study.Clinical epigenetics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPrecision medicine in psychiatry is still in its infancy. To establish patient-tailored treatment, adequate indicators predicting treatment response are required. Electroconvulsive therapy (ECT) is considered one of the most effective options for pharmacoresistant major depressive disorder (MDD), yet remission rates were reported to be below 50%.
methodsSince epigenetics of the stress response system seem to play a role in MDD, we analyzed the DNA methylation (DNAm) of genes encoding the glucocorticoid receptor (
resultsBaseline DNAm in DISCUSSION: Our findings indicate that both genes might play a role in the chronification of depression and
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.